228 related articles for article (PubMed ID: 24631739)
1. Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma.
Rueff J; Medinger M; Heim D; Passweg J; Stern M
Biol Blood Marrow Transplant; 2014 Jun; 20(6):896-9. PubMed ID: 24631739
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT.
Bühlmann L; Buser AS; Cantoni N; Gerull S; Tichelli A; Gratwohl A; Stern M
Bone Marrow Transplant; 2011 Oct; 46(10):1357-62. PubMed ID: 21113185
[TBL] [Abstract][Full Text] [Related]
3. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
[TBL] [Abstract][Full Text] [Related]
4. Impact of very early CD4(+) /CD8(+) T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation.
Huttunen P; Taskinen M; Siitonen S; Saarinen-Pihkala UM
Pediatr Blood Cancer; 2015 Mar; 62(3):522-8. PubMed ID: 25417898
[TBL] [Abstract][Full Text] [Related]
5. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[TBL] [Abstract][Full Text] [Related]
6. Reconstitution of lymphocyte subpopulations after hematopoietic stem cell transplantation: comparison of hematologic malignancies and donor types in event-free patients.
Park BG; Park CJ; Jang S; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH
Leuk Res; 2015 Dec; 39(12):1334-41. PubMed ID: 26422556
[TBL] [Abstract][Full Text] [Related]
7. Status of Natural Killer Cell Recovery in Day 21 Bone Marrow after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome.
Hattori N; Saito B; Sasaki Y; Shimada S; Murai S; Abe M; Baba Y; Watanuki M; Fujiwara S; Kawaguchi Y; Arai N; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Harada H; Nakamaki T
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1841-1847. PubMed ID: 29753837
[TBL] [Abstract][Full Text] [Related]
8. Naive Donor NK Cell Repertoires Associated with Less Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Björklund AT; Clancy T; Goodridge JP; Béziat V; Schaffer M; Hovig E; Ljunggren HG; Ljungman PT; Malmberg KJ
J Immunol; 2016 Feb; 196(3):1400-11. PubMed ID: 26746188
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients.
Heining C; Spyridonidis A; Bernhardt E; Schulte-Mönting J; Behringer D; Grüllich C; Jakob A; Bertz H; Finke J
Bone Marrow Transplant; 2007 May; 39(10):613-22. PubMed ID: 17384658
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
11. Progress in allogeneic transplantation for multiple myeloma.
Gahrton G
Eur J Haematol; 2010 Oct; 85(4):279-89. PubMed ID: 20608964
[TBL] [Abstract][Full Text] [Related]
12. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
13. Assessment of immune reconstitution status in recipients of a successful hematopoietic stem cell transplant from peripheral blood after reduced intensity conditioning.
Jaime-Pérez JC; Villarreal-Villarreal CD; Méndez-Ramírez N; Vázquez-Garza E; Salazar-Riojas R; Gómez-Almaguer D
Blood Cells Mol Dis; 2016 May; 58():52-6. PubMed ID: 27067489
[TBL] [Abstract][Full Text] [Related]
14. Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab.
Matthews K; Lim Z; Pearce L; Pagliuca A; Alejandro Madrigal J; Mufti GJ; Barber LD
Br J Haematol; 2010 Jun; 149(6):879-89. PubMed ID: 20346011
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival.
Dean R; Masci P; Pohlman B; Andresen S; Serafino S; Sobecks R; Kuczkowski E; Curtis J; Maciejewski J; Rybicki L; Kalaycio M; Hsi E; Theil K; Bolwell BJ
Bone Marrow Transplant; 2005 Dec; 36(12):1049-52. PubMed ID: 16247431
[TBL] [Abstract][Full Text] [Related]
16. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation.
Kim DH; Won DI; Lee NY; Sohn SK; Suh JS; Lee KB
Biol Blood Marrow Transplant; 2006 Jul; 12(7):719-28. PubMed ID: 16785061
[TBL] [Abstract][Full Text] [Related]
17. Immune reconstitution and early infectious complications following nonmyeloablative hematopoietic stem cell transplantation.
Busca A; Lovisone E; Aliberti S; Locatelli F; Serra A; Scaravaglio P; Omedè P; Rossi G; Cirillo D; Barbui A; Ghisetti V; Dall'Omo AM; Falda M
Hematology; 2003 Oct; 8(5):303-11. PubMed ID: 14530172
[TBL] [Abstract][Full Text] [Related]
18. Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation.
Servais S; Lengline E; Porcher R; Carmagnat M; Peffault de Latour R; Robin M; Sicre de Fontebrune F; Clave E; Maki G; Granier C; Xhaard A; Dhedin N; Molina JM; Toubert A; Moins-Teisserenc H; Socie G
Biol Blood Marrow Transplant; 2014 Apr; 20(4):507-17. PubMed ID: 24406505
[TBL] [Abstract][Full Text] [Related]
19. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery.
Gärtner F; Hieke S; Finke J; Bertz H
Cytotherapy; 2013 Oct; 15(10):1237-44. PubMed ID: 23993297
[TBL] [Abstract][Full Text] [Related]
20. Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation.
Larosa F; Marmier C; Robinet E; Ferrand C; Saas P; Deconinck E; Bulabois CE; Rohrlich PS; Ledu K; Helias P; Tiberghien P; Cahn JY
Bone Marrow Transplant; 2005 May; 35(9):859-68. PubMed ID: 15765116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
